Figure 5.

Therapy-treated OB-RES mice have a robust CD4⁺ TIL effector response that is lacking in DIO mice. (A) CD44⁺CD4⁺ TILs at day 17–18, day 21, and day 27–28 post-tumor challenge across groups. (B) Cell viability and death markers at day 21 post-tumor challenge in CD44⁺CD4⁺ TILs. (C) Intracellular expression of IFNγ and (D) the mean fluorescent intensity of IFNγ in ex vivo stimulated CD44⁺CD4⁺ TILs at day 21 post-tumor challenge. (E) IFNγ⁺CD44⁺CD4⁺ TILs as a percent of single cells at day 21 post-tumor challenge. Data from n = 2–5 independent experiments. Fold change value calculated using no therapy control for each group. ^# denotes non-parametric test. ^# p < 0.05, ^## p < 0.01, ^### p < 0.001. ns: non-significant, NT: no therapy, TX: AdT/CpG+αCTLA-4.